Development of universal influenza vaccines: strategies for broadly cross-reactive influenza vaccine responses.
Saved in:
| Title: | Development of universal influenza vaccines: strategies for broadly cross-reactive influenza vaccine responses. |
|---|---|
| Authors: | Li, Mengling1,2,3 (AUTHOR), Guo, Pengju1,2,3 (AUTHOR), Song, Haiguang1,2,3 (AUTHOR), Chen, Cen4 (AUTHOR), Zhou, Hongbo1,2,3 (AUTHOR), Tao, Pan1,2,3 (AUTHOR) taopan@mail.hzau.edu.cn |
| Source: | Animal Diseases. 8/21/2025, Vol. 5 Issue 1, p1-21. 21p. |
| Document Type: | Article |
| Subjects: | Influenza vaccines, Antigens, Immune response, Intranasal administration, Vaccine effectiveness, Preventive medicine, Influenza viruses |
| Author-Supplied Keywords: | Conserved antigens Influenza Medical and Health Sciences Immunology Mucosal immunity TRM Universal vaccines |
| Abstract: | Influenza virus remains a significant global health threat because of its ability to evolve rapidly and cause both seasonal epidemics and global pandemics. Although seasonal influenza vaccines provide some protection, their effectiveness depends on accurate prediction and annual reformulation to antigenically match circulating strains. Mismatches between vaccine strains and circulating viruses can significantly reduce protective efficacy. Universal influenza vaccines aim to overcome these limitations by eliciting broad and long-lasting immunity against conserved viral components. Recent strategies have focused on targeting conserved antigens shared across diverse strains, such as the HA stem, M2e, NP, and M1, and on employing platforms, including chimeric constructs, peptide ensembles, DNA/RNA-based approaches, and virus-like particles. In parallel, mucosal delivery, particularly via the intranasal route, has gained attention for its ability to induce secretory IgA and tissue-resident memory T (TRM) cells, which provide cross-protective immunity at the respiratory barrier. This review highlights key advances and persistent challenges in the development of broadly cross-reactive influenza vaccines, with emphasis on conserved antigen design, mucosal immunity, delivery strategies, and future directions toward achieving universal protection against both seasonal and pandemic influenza strains. [ABSTRACT FROM AUTHOR] |
| Copyright of Animal Diseases is the property of BioMed Central and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Author Affiliations: | 1https://ror.org/023b72294 State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, 430070, Wuhan, Hubei, China 2Hubei Hongshan Lab, 430070, Wuhan, Hubei, China 3https://ror.org/023b72294 Cooperative Innovation Center for Sustainable Pig Production, College of Veterinary Medicine, Huazhong Agricultural University, 430070, Wuhan, Hubei, China 4Xiaogan Agricultural Technology Extension Center, 432000, Xiaogan, Hubei, China |
| Full Text Word Count: | 18984 |
| ISSN: | 2731-0442 |
| DOI: | 10.1186/s44149-025-00187-6 |
| Accession Number: | 187459735 |
| Database: | Veterinary Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Influenza virus remains a significant global health threat because of its ability to evolve rapidly and cause both seasonal epidemics and global pandemics. Although seasonal influenza vaccines provide some protection, their effectiveness depends on accurate prediction and annual reformulation to antigenically match circulating strains. Mismatches between vaccine strains and circulating viruses can significantly reduce protective efficacy. Universal influenza vaccines aim to overcome these limitations by eliciting broad and long-lasting immunity against conserved viral components. Recent strategies have focused on targeting conserved antigens shared across diverse strains, such as the HA stem, M2e, NP, and M1, and on employing platforms, including chimeric constructs, peptide ensembles, DNA/RNA-based approaches, and virus-like particles. In parallel, mucosal delivery, particularly via the intranasal route, has gained attention for its ability to induce secretory IgA and tissue-resident memory T (TRM) cells, which provide cross-protective immunity at the respiratory barrier. This review highlights key advances and persistent challenges in the development of broadly cross-reactive influenza vaccines, with emphasis on conserved antigen design, mucosal immunity, delivery strategies, and future directions toward achieving universal protection against both seasonal and pandemic influenza strains. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 27310442 |
| DOI: | 10.1186/s44149-025-00187-6 |